Advanced Kidney Cancer Management for Urologists - Anil Kapoor

Advanced Kidney Cancer Management: Systemic Therapy Management for Urologists - How I Do It

Presentation from the 2017 Annual LUGPA meeting in Chicago, IL

(Length of Presentation: 26 min)

Dr. Anil Kapoor presents Advanced Kidney Cancer Management: Targeted Agents and Immunotherapy - Establishing a Clinic of Excellence at the 2017 LUGPA annual meeting. He discusses first-line therapies for metastatic renal cell cancer, incorporating real-world data into current treatment algorithms. He walks the listener through the current landscape of first-line RCC trials including the COMPARZ study and it’s comparative data.  A study that was developed to help treating physicians drill down on their first-line treatment options in Metastatic RCC when comparing Sunitinib vs IFN-a or Pazopanib vs Placebo.  The COMPARZ study randomized patients with Pazopinib and Sunitinib.  Dr. Anil Kapoor highlights the study findings showing that the Pazopinib is non-inferior to, and equivalent to Sunitinib and how it is found that Pazopinib may have some less toxicity and suggests a more favorable tolerability profile compare to Sunitinib. Dr. Kapoor details managing TKI and IO toxicities and incorporating mRCC patient management into your own practice.

View More Session Coverage of LUGPA 2017


Anil Kapoor, MD, FRCSC St. Joseph’s Healthcare, Hamilton, ON

Professor, Urology, Director of Research, Division of Urology, Program Director, Urology Residency Program, Surgical Director, Renal Transplantation, St. Joseph’s Hospital, Chair, Genito-Urinary Oncology Program, Juravinski Cancer Centre

Dr. Anil Kapoor’s main area of research focus is kidney disease, including renal cell carcinoma and renal transplantation. Recent investigations include cell signaling pathways involved in localized and metastatic renal cell cancer, examining the role of pTEN, cdk11, and the mTOR pathway; and therapeutic targeting of the mTOR pathway using the mTOR inhibitors, in metastatic renal cell cancer. In the transplant field, examination of the role of mTOR inhibitors in allograft function and malignancy including the cell signaling pathways. Other areas of research interest include the role of minimally invasive surgery in the treatment of urologic malignancies, including robotic platforms.